Results 181 to 190 of about 3,166,261 (352)

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

A dual-branch deep learning network for circulating tumor cells classification. [PDF]

J Transl Med
Han C, Lin J, Liang Y, Li C, Wang D, Huang G, Hong R, Zeng J.   +7 more
europepmc   +1 more source

Studies of the Mode of Infection of <i>Rickettsia orientalis</i> (Ozeki Strain) in Ehrlich Ascites Tumor Cells

, 1959
Kiyoshi Aikawa
openalex   +2 more sources

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source

Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy. [PDF]

Sci Adv
Liu J, Herbrich S, Basu S, Chen Y, Nagarajan A, Anandhan S, Goswami S, Xiong L, Guan B, Sharma P.   +9 more
europepmc   +1 more source

THE EFFECT OF ANTIBODY ON INTRACELLULAR VACCINIA VIRUS MULTIPLICATION IN THE EHRLICH ASCITES TUMOR CELLS

, 1959
Eiichi Furusawa, Kumao Toyoshima, Tadashi Miyagawa   +2 more
openalex   +2 more sources

The mechanism of viral carcinogenesis by DNA mammalian viruses: viral-specific RNA in polyribosomes of adenovirus tumor and transformed cells. [PDF]

, 1966
Kei Fujinaga, M Green
openalex   +1 more source

Emerging role of ARHGAP29 in melanoma cell phenotype switching

Molecular Oncology, EarlyView.
This study gives first insights into the role of ARHGAP29 in malignant melanoma. ARHGAP29 was revealed to be connected to tumor cell plasticity, promoting a mesenchymal‐like, invasive phenotype and driving tumor progression. Further, it modulates cell spreading by influencing RhoA/ROCK signaling and affects SMAD2 activity. Rho GTPase‐activating protein
Beatrice Charlotte Tröster, Melanie Kappelmann‐Fenzl, Anja Katrin Bosserhoff, Nicole Rachinger   +3 more
wiley   +1 more source

Resilience and vulnerabilities of tumor cells under purine shortage stress. [PDF]

Clin Cancer Res
Yu J, Jin C, Su C, Moon D, Sun M, Zhang H, Jiang X, Zhang F, Tserentsoodol N, Bowie ML, Pirozzi CJ, George D, Wild R, Gao X, Ashley DM, He Y, Huang J.   +16 more
europepmc   +1 more source

On the Relationship of Ehrlich Ascites Tumor Cells to Tsutsugamushi Disease Rickettsiae

, 1959
Reiji Yagi
openalex   +2 more sources